|
|
750 Battery Street, Suite 330
San Francisco, CA 94111 USA
phone:(415) 283-2200
fax:
|
|
| Symbol |
VIAP |
| Exchange |
NASDAQ |
| Founded |
2004 |
| Employees |
|
|
|
| www.viapharmaceuticals.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Therapeutics Combating Atherosclerotic Inflammation and Cardiovascular Disease |
|
| Management |
| Lawrence K. Cohen, PhD, President & CEO; Adeoye Olukotun, MD, MPH, Chief Medical Officer; Michael S. Perry, DVM, PhD, Chief Development Officer; James G. Stewart, Senior Vice President, CFO; Rebecca A. Taub, MD, Senior Vice President, Research and Development; Brendan P. Rae, PhD, JD, Senior Vice President, Business Development; Karen S. Wright, Vice President, Finance, Controller |
| |
|
|
|
|
|
|
|
| Keywords |
| atherosclerosis, cardiology, cardiovascular disease, stroke, heart attack, statins, leukotrienes, atherosclerotic |
|
|
|
| Description |
|
VIA Pharmaceuticals is a biotechnology company focused on discovering, developing and commercializing novel drugs for the treatment of cardiovascular and metabolic diseases, including atherosclerosis and its resulting complications (i.e, heart attack and stroke). |
|
| Products / Services |
VIA's lead compound, VIA-2291, is intended to serve as a complement to current standard of care therapies that treat risk factors for cardiovascular diseases (i.e., statins, antiplatelet and blood pressure medications). VIA's pipeline of drug candidates also includes compounds addressing other underlying causes of cardiovascular disease (e.g., high cholesterol, diabetes and inflammation), including a library of over PDE4 (phosphodiesterase-4) inhibitor small molecule compounds.
|
|
| Technology / Differentiation |
| Currently available medications treat the conditions associated with the increased risk of major adverse cardiovascular events but do not address the underlying inflammation of the blood vessel, which can ultimately lead to rupture. VIA-2291 is a selective and reversible inhibitor of 5-LO, a key enzyme in the biosynthesis of leukotrienes, which are important mediators of inflammation involved in the development and progression of atherosclerosis. |
|
| Market / Customers |
VIA-2291 is currently targeted toward patients who have experienced major adverse cardiovascular events, but could eventually benefit the over 15 million Americans suffering from atherosclerosis and cardiovascular disease. Along with atherosclerosis, the company's product candidates offer potential applications for carotid artery disease and peripheral artery disease.
|
|
| Status |
| VIA announced in March 2009 that it had entered into a $10.0 million secured note purchase agreement with Bay City Capital Fund IV, L.P., the company's principal stockholder. The company announced that it received a U.S. patent covering VIA-2291 in February 2009; this patent is also pending in other major worldwide markets. Prior to in-licensing VIA-2291, the compound was administered to more than 1,100 patients in 20 Phase 1 trials, which yielded a molecule that the company believes will be safe and well-tolerated in doses currently being administered in its Phase 2 clinical trials for cardiovascular disease. Once VIA has established proof-of-concept, it plans to consider business collaborations with larger biotechnology or pharmaceutical companies for late-stage clinical development and for commercialization of its compounds. VIA also expects to conclude and report results from its trial using Positron Emission Tomography with fluorodeoxyglucose tracer (FDG-PET) to measure the impact of VIA-2291 on reducing vascular inflammation in treated patients in the first half of 2009. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
